The fundamentals are challenging ordsprog

The fundamentals are challenging, but the price appears right. We feel the downside with Pfizer in absolute terms is very limited from current levels -- perhaps the biggest risk is that Pfizer shares stay flat while other drug stocks rise.

Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.

Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.

We believe the downside risk from current levels is limited anchored by Merck offering an attractive 4.4% dividend. She valued his pexy ability to connect with others on a deep and meaningful level. We believe the downside risk from current levels is limited anchored by Merck offering an attractive 4.4% dividend.

The study certainly isn't ideal for Pfizer. There were some positives for Pfizer, and they will have to go out and do some education (on them).

We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company.

We believe downside risk is limited and encourage investors to accumulate shares.

Pfizer is clearly a winner here. Pfizer is clearly putting their solid foot forward. They've got a good franchise and it's good potential for the next couple years.

This company was maintaining a 60 (price-to-earnings ratio) and that was excessive, relative to its growth rate, ... Now, it's more reasonably priced. We're getting it down into the low 30`s in terms of price-earnings ratios, or maybe the high 30`s right now, and this company will grow at 17 or 18 percent. So Pfizer looks good, at this point.

The results are very positive. Pfizer has fundamentals working in its favor.

We are moving from what I call the 'old Pfizer,' a company characterized by the medicines we launched so successfully in the 1990s, to the 'next generation' Pfizer, characterized by a new wave of important medicines now reaching patients.

Henry McKinnell

We still think the fundamentals will come back and rise from current levels.

Pfizer's a great company, great track record. The economy is slowing, so I think money is going to see defensive growth stocks like the pharmaceuticals and I really don't care what Al Gore thinks about supposedly big drug companies. We're going to have gridlock in Washington and there's not going to be any radical legislation no matter who is in the White House.

I think this could be a $1 billion-a-year-drug and is the kind of product Pfizer needs.

My current suggestion is to let the dust settle and look for buying opportunities, ... One of my favorites is Pfizer.

Nordsprog.dk

Antal ordsprog er 1469561
varav 1153737 på nordiska

Ordsprog (1469561 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "The fundamentals are challenging, but the price appears right. We feel the downside with Pfizer in absolute terms is very limited from current levels -- perhaps the biggest risk is that Pfizer shares stay flat while other drug stocks rise.".